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Over the last 20 years, after combining treatment of chemotherapy and radiotherapy, there has been an improvement
in the survival rate of acute lymphoblastic leukemia patients, with a current cure rate of around 70%. Children with the
disease have been enrolled into international treatment protocols designed to improve survival and minimize the serious
irreversible late effects. Our oncology unit uses the international protocol: GBTLI LLA-85 and 90, with the drugs
methotrexate, cytosine, arabinoside, dexamethasone, and radiotherapy. However, these treatments can cause gonadal
damage and growth impairment.
PATIENTS AND METHOD: The authors analyzed 20 children off therapy in order to determine the role of the
various doses of radiotherapy regarding endocrinological alterations. They were divided into 3 groups according to
central nervous system prophylaxis: Group A underwent chemotherapy, group B underwent chemotherapy plus radiotherapy
(18 Gy), and group C underwent chemotherapy plus radiotherapy (24 Gy). Serum concentrations of LH, FSH, GH, and
testosterone were determined. Imaging studies included bone age, pelvic ultrasound and scrotum, and skull magnetic
resonance imaging.
RESULTS: Nine of the patients who received radiotherapy had decreased pituitary volume. There was a significant
difference in the response to GH and loss of predicted final stature (Bayley-Pinneau) between the 2 irradiated groups and
the group that was not irradiated, but there was no difference regarding the radiation doses used (18 or 24 Gy). The final
predicted height (Bayley-Pinneau) was significantly less (P = 0.0071) in both groups treated with radiotherapy. Two girls
had precocious puberty, and 1 boy with delayed puberty presented calcification of the epididymis.
CONCLUSION: Radiotherapy was been responsible for late side effects, especially related to growth and puberty.
KEY WORDS: Endocrine dysfunction in lymphoblastic leukemia. Growth and acute leukemia. Puberty in
lymphoblastic leukemia.
Advances in oncologic therapy
have increased the survival rates of
childhood acute lymphoblastic
leukemia (ALL), but the aggressive
nature of chemotherapy (ChT) and ra-
diotherapy (RT) can damage normal
tissues and hence affect the endocrine
glands, leading to hormonal dysfunc-
tions. Among other effects, the iatro-
genic effects of treatment may affect
growth and puberty. In treatment for
ALL, different protocols have been de-
signed to improve survival and mini-
mize late effects. It seems as though the
younger the patient, the greater the
potential for late effects of treatment1,2.
The objective of this paper is to re-
late the influence of the basic disease,
the age of child, as well as the treat-
ment (ChT and or RT) on growth and
puberty according to the different
protocols used in our unit.
PATIENTS AND METHOD
Twenty patients (12 boys, 8 girls)
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were sequentially studied, all treated
for ALL, being in remission at least for
2 years. Their ages ranged from 8 to
17 years at the endocrinological evalu-
ation (Table 1). None of them had ini-
tial central nervous system involve-
ment. Nine of them were older than 12
years. The patients were enrolled into
an international protocol (GBTLI
LLA-85 and 90) for 2.5 years. They
were divided into 3 groups according
to CNS prophylaxis: A) 5 patients un-
derwent ChT (intrathecal methotrexate,
cytosine, arabinoside, and dexametha-
sone); B) 6 patients underwent ChT
plus RT with 18 Gy; and C) 9 patients
underwent ChT plus RT with 24 Gy.
Serum concentrations of LH, FSH,
GH, and testosterone were determined
by immunofluorometric assay (IFMA)
using commercially available kits
(Delphia-Pharmacia Diagnostic) after
stimulation with GnRH, glucagon/insu-
lin, and hCG, respectively. The cut-off
limits of GnRH-stimulated LH to dis-
tinguish prepubertal and pubertal sub-
jects were 9.6 IU/L in boys and 6.9 IU/
L in girls3. Normal response for testo-
sterone was considered to be >160 ng/
dL or >150 ng/dL above basal levels.
Seventeen patients underwent 2 tests
for GH, and the remaining 3 underwent
only 1 test. A normal response for GH
after stimulation was considered to be
³10 ng/dL4. Imaging studies included
bone age (Greulich-Pyle), pelvic ultra-
sound, and scrotum and skull magnetic
resonance imaging (MRI). We deter-
mined the pubertal stage using the Tan-
ner criteria, and we defined growth de-
ficiency as height below the 3rd percen-
tile or –2.0 SD (NCHS).
RESULTS
In 9 of the patients who received
RT, mainly in group C (24 Gy) the pi-
tuitary volume as determined by MRI
was decreased. In 13 out of 15 patients
from groups B and C, and 1 from group
A, stimulation tests revealed a low GH
response: peak <5.7 ng/mL. Both
groups B and C had low height after
RT regardless the dose used (18 or 24
Gy). Groups B and C had low GH re-
sponse to glucagon, which was signifi-
cantly different when compared to
group A (P = 0.0087). No difference
was observed between groups B and
C. The final predicted height (Bayley-
Pinneau) was significantly less (P =
0.0071) in both groups treated with RT,
compared to group A. Groups B (60%)
and C (83%) had a lower growth ve-
Table 1 - Anthropometric growth and pubertal data of the children.
Group A - True Basic Risk - no RT; Group B - Basic Risk - 18 Gy RT; Group C - High Risk - 24 Gy RT; OT: out of therapy; CA: chronological
age; BA: bone age; GV: growth velocity; TH: target height; US: ultrasound; MRI: magnetic resonance image; GH: stimulation test; glucagon and/
or clonidine test; N: normal; Calcif E: calcification of the epididymis 
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locity compared to group A (20%).
On the other hand, concerning the
impact of cytotoxic agents on gonadal
function and pubertal development in
this study, 2 girls had precocious pu-
berty (groups A and C) and one 17-yr-
old boy with epididymis calcification
had delayed puberty (stimulated testo-
sterone was 46 ng/dL). All of the 15
pubertal patients showed normal basal
and peak LH and FSH levels after the
GnRH test.
DISCUSSION
The aggressive nature of ALL
therapy is responsible for neoplastic
cell eradication, but the iatrogenic ef-
fects can affect the child’s growth and
normal endocrine functions, leading to
pituitary and gonadal deficiencies4-8.
The consequences are especially se-
vere in children, since developing tis-
sue is highly susceptible to damage.
The drugs can cause precocious toxic
effects, but the late effects are mainly
due to RT9-11 .
Children who were very young at
the time of irradiation tend to develop
sequelae such as growth impairment
and early puberty12,13. Only one 3-year-
old girl among the 5 patients of the
group A showed low levels of GH and
a reduction in predicted final height.
The GH stimulation test revealed sig-
nificantly different levels of the hor-
mone between irradiated and non-irra-
diated groups (P = 0.0087), although
no difference was found regarding the
dose of radiation. We observed a reduc-
tion in predicted final height (Bayley-
Pinneau) of the ChT plus RT-treated as
compared to the ChT-treated groups (P
= 0.0071), but we found no difference
with regard to the dose of radiation.
Thirteen of the 14 GH deficient pa-
tients belonged to the irradiated group,
and 10 of them had significant height
loss predictions. The 2 patients who
had the most severe short stature
(Bayley-Pinneau) were girls irradiated
with 24 Gy before 8 years of age. Some
authors have concluded that the severe
late sequelae of radiation therapy are
dose related. However, there is no con-
sensus about the correlation between
the dose of 18 Gy or 24 Gy of irradia-
tion and the sequelae. In this study, in
spite the fact that 16 patients had low
GH levels in 2 stimulating tests, only
6 of them had a loss of predicted
height, probably because they were
exposed to lower doses (18 or 24 Gy)
of cranial irradiation. Nevertheless, it
is well known that the hypothalamus
appears to be more radiosensitive than
the pituitary gland, and the GH defi-
ciency seems to result from disruption
of the GHRH/somatostatin feedback
mechanisms14. Evidence suggests that
of all the pituitary hormones, GH is the
most radiosensitive, showing impaired
24-hour profiles14. Some of these chil-
dren can benefit from GH therapy. The
success of the therapy depends on the
age and puberty stage of these chil-
dren.
The MRI showed some alterations
in 13 patients: small pituitary (9 pa-
tients), stalk deviation, pineal cyst,
bulgy pituitary, and basal nucleus cal-
cification (1 each). Eight of these pa-
tients had been exposed to 24 Gy.
After treatment for ALL with low
doses of cranial irradiation, girls ap-
pear to be particularly susceptible to
the development of precocious pu-
berty. The earlier growth spurt at pu-
berty can mask the growth impairment
in these children.
Ovarian development in girls
treated for ALL may be affected by cy-
totoxic agents15. Girls treated with ei-
ther craniospinal or abdominal irradia-
tion for ALL may develop abnormali-
ties of both LH and FSH16. They can ex-
perience precocious or delayed puberty.
Two boys presented low testosterone
responses to hCG, and 1 of them pre-
sented calcification of the epididymis,
delayed puberty, and delayed bone age
without growth impairment. One girl
had an enlarged uterus and LH peak
level of 35UI/mL. Two girls showed
clinical signs of early puberty.
In conclusion, the groups that un-
derwent RT showed significant growth
impairment irrespective of the dose of
irradiation (18 or 24 Gy). The impact
on pubertal development was appar-
ently less pronounced. It is important
to remember that the group that
needed RT had the most severe form
of disease, and we cannot rule out the
impact of the disease itself on these
hormonal dysfunctions. It is important
to keep in mind that since leukemia is
a treatable disease, dysfunctions, espe-
cially on growth, cannot be underesti-
mated, and short stature is an impor-
tant sequelae that needs treatment
whenever detected.
RESUMO
ALVES CHB da S e col. - Crescimen-
to e puberdade após tratamento da
leucemia linfoblástica aguda. Rev.
Hosp. Clín. Fac. Med. S. Paulo
59(2):67-70, 2004.
Nos últimos 20 anos, após o trata-
mento de pacientes portadores de
leucemia linfoblástica aguda, com
quimioterapia e radioterapia, houve
melhora na taxa de sobrevivência e cura
em torno de 70%. Crianças portadoras
da doença foram envolvidas em proto-
colos de tratamento internacionais que
visavam melhorar a sobrevida e
minimizar os graves e irreversíveis efei-
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tos tardios. A nossa unidade utiliza o
protocolo internacional GBTLI LLA-
85 e 90, com as drogas metrotexate,
citosina, arabinoside, dexametasona e
radioterapia .Entretanto, estes tratamen-
tos podem causar insuficiências
gonadais e prejuízo no crescimento.
PACIENTES E MÉTODO: Os au-
tores analisaram 20 crianças fora de te-
rapia a fim de determinar o papel das
várias doses de radioterapia sobre al-
terações endocrinológicas. Foram divi-
didos em três grupos baseados na
profilaxia do sistema nervoso central:
o grupo A foi submetido à quimio-
terapia, o grupo B à quimioterapia
mias radioterapia (18Gy) e o grupo C
à quimioterapia mais radioterapia (24
Gy). Foram avaliadas as concentrações
séricas de LH, FSH, GH e testosterona.
Os estudos de imagem incluiram ida-
de óssea, ultrassonografia pélvica,
escrotal e ressonância nuclear magné-
tica do crânio.
RESULTADOS: Houve diferenças
significativas nas respostas do hor-
mônio de crescimento e prejuízo na
estatura final (Bayley-Pinneau) entre
os dois grupos irradiados e o grupo
que não foi irradiado, mas não houve
diferenças quando se compararam as
doses de radiação utilizadas (18 ou 24
Gy). A previsão da altura final (Bayley-
Pinneau) foi menor (p= 0,0071) nos
dois grupos tratados com radioterapia.
Duas meninas apresentaram puberda-
de precoce e um menino teve atraso
puberal associado a calcificação do
epidídimo.
CONCLUSÃO: A radioterapia é
responsável por efeitos colaterais espe-
cialmente quanto ao crescimento e pu-
berdade.
UNITERMOS: Disfunção endó-
crina na leucemia linfoblástica. Cres-
cimento e leucemia aguda. Puberda-
de na leucemia linfoblástica.
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